Molecular profiling of NSCLC found higher gene mutations in multiple oncogenes, such as epidermal growth factor receptor (EGFR) (10–35%), K-ras (KRAS) (15–25%), and Phosphatase and tensin homolog (PTEN) (4–8%). This evidence concerns the gene KRAS and non-small cell lung carcinoma.